Vyant Bio, Inc. (VYNT) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Cherry Hill, NJ, United States. El CEO actual es Andrew D.C. LaFrence CPA.
VYNT tiene fecha de IPO 2021-04-01, 4 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke.
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.
